Ariana M Chao1,2, Thomas A Wadden2, Jeanne M Clark3, Kathleen M Hayden4, Marjorie J Howard4, Karen C Johnson5, Blandine Laferrère6, Jeanne M McCaffery7, Rena R Wing8, Susan Z Yanovski9, Lynne E Wagenknecht4. 1. 1Department of Biobehavioral Health Sciences, University of Pennsylvania School of Nursing, Philadelphia, PA. 2. 2Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA. 3. 3Division of General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, MD. 4. 4Wake Forest School of Medicine, Winston-Salem, NC. 5. 5Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, TN. 6. 6Columbia University Irving Medical Center, New York, NY. 7. 7University of Connecticut, Storrs, CT. 8. 8The Warren Alpert Medical School of Brown University, Providence, RI. 9. 9National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.
Abstract
OBJECTIVE: To evaluate changes in the prevalence of depressive symptoms, loneliness, and insomnia among older adults with type 2 diabetes from 2016 to 2020 and to assess risk factors for these conditions including demographics, multimorbidity, BMI, treatment group, and pre-coronavirus 2019 (COVID-19) measure scores. RESEARCH DESIGN AND METHODS: This was a prospective, observational study of participants from the Look AHEAD (Action for Health in Diabetes) cohort study. Data were from two assessments before COVID-19 (visit 1: April 2016-June 2018 and visit 2: February 2018-February 2020) and one assessment during COVID-19 (visit 3: July-December 2020). Surveys were administered to assess depressive symptoms, loneliness, and insomnia. RESULTS: The study included 2829 adults (63.2% female, 60.6% White, mean [SD] age 75.6 [6.0] years). The prevalence of mild or greater depressive symptoms did not change significantly between the two pre-pandemic visits (P = 0.88) but increased significantly from pre- to during COVID-19 (19.3% at V2 to 30.4% at V3; P < 0.001). Higher odds of mild or greater depressive symptoms at V3 were associated with being female (adjusted odds ratio [OR] 1.4 [95% CI 1.1-1.7]), identifying as non-Hispanic White (OR 1.4 [95% CI 1.1-1.7]), having obesity (OR 1.3 [95% CI 1.0-1.5]), and reporting mild or greater depressive symptoms at V1 (OR 4.0 [95% CI 2.9-5.4]), V2 (OR 4.4 [95% CI 3.2-5.9]), or both visits (OR 13.4 [95% CI 9.7-18.4]). The prevalence of loneliness increased from 12.3% at V1 to 22.1% at V3 (P < 0.001), while the prevalence of insomnia remained stable across visits at 31.5-33.3%. CONCLUSIONS: The prevalence of mild or greater depressive symptoms in older adults with diabetes was more than 1.6 times higher during COVID-19 than before the pandemic.
OBJECTIVE: To evaluate changes in the prevalence of depressive symptoms, loneliness, and insomnia among older adults with type 2 diabetes from 2016 to 2020 and to assess risk factors for these conditions including demographics, multimorbidity, BMI, treatment group, and pre-coronavirus 2019 (COVID-19) measure scores. RESEARCH DESIGN AND METHODS: This was a prospective, observational study of participants from the Look AHEAD (Action for Health in Diabetes) cohort study. Data were from two assessments before COVID-19 (visit 1: April 2016-June 2018 and visit 2: February 2018-February 2020) and one assessment during COVID-19 (visit 3: July-December 2020). Surveys were administered to assess depressive symptoms, loneliness, and insomnia. RESULTS: The study included 2829 adults (63.2% female, 60.6% White, mean [SD] age 75.6 [6.0] years). The prevalence of mild or greater depressive symptoms did not change significantly between the two pre-pandemic visits (P = 0.88) but increased significantly from pre- to during COVID-19 (19.3% at V2 to 30.4% at V3; P < 0.001). Higher odds of mild or greater depressive symptoms at V3 were associated with being female (adjusted odds ratio [OR] 1.4 [95% CI 1.1-1.7]), identifying as non-Hispanic White (OR 1.4 [95% CI 1.1-1.7]), having obesity (OR 1.3 [95% CI 1.0-1.5]), and reporting mild or greater depressive symptoms at V1 (OR 4.0 [95% CI 2.9-5.4]), V2 (OR 4.4 [95% CI 3.2-5.9]), or both visits (OR 13.4 [95% CI 9.7-18.4]). The prevalence of loneliness increased from 12.3% at V1 to 22.1% at V3 (P < 0.001), while the prevalence of insomnia remained stable across visits at 31.5-33.3%. CONCLUSIONS: The prevalence of mild or greater depressive symptoms in older adults with diabetes was more than 1.6 times higher during COVID-19 than before the pandemic.
Authors: M Hall; D J Buysse; P D Nowell; E A Nofzinger; P Houck; C F Reynolds; D J Kupfer Journal: Psychosom Med Date: 2000 Mar-Apr Impact factor: 4.312
Authors: Mark É Czeisler; Rashon I Lane; Emiko Petrosky; Joshua F Wiley; Aleta Christensen; Rashid Njai; Matthew D Weaver; Rebecca Robbins; Elise R Facer-Childs; Laura K Barger; Charles A Czeisler; Mark E Howard; Shantha M W Rajaratnam Journal: MMWR Morb Mortal Wkly Rep Date: 2020-08-14 Impact factor: 17.586
Authors: Lynne E Wagenknecht; Ariana M Chao; Thomas A Wadden; Jeanne M McCaffery; Kathleen M Hayden; Blandine Laferrère; Jeanne M Clark; Karen C Johnson; Marjorie J Howard; Susan Z Yanovski; Rena R Wing Journal: Obesity (Silver Spring) Date: 2022-05-06 Impact factor: 9.298